Novigenix, a leader in AI-driven precision liquid biopsy solutions, has been awarded EUR 1.8M through the new BRECISE IHI grant funded by the European Union (EU) research initiative focusing on revolutionizing cancer diagnostics, treatment, and monitoring through advanced multi-omics and artificial intelligence.
The BRECISE consortium was launched last week in Madrid at its face-to-face kick-off meeting during the 40th meeting of the European Association of Urology Congress. The multi-stakeholder collaborative effort, co-funded by the Innovative Health Initiative (IHI) under the Horizon Europe program, aims to transform patient care by integrating Next-Generation Sequencing (NGS)-based biomarkers with AI-driven decision-making frameworks.
BRECISE seeks to address critical challenges in oncology, particularly in prostate and bladder cancer, by accelerating the clinical validation of multi-modal biomarkers.
